Aranda Pharma

Executive Summary

Aranda Pharma is a Finnish preclinical-stage biotechnology company developing novel, non-steroidal small molecule inhibitors of the androgen receptor for topical treatment of androgenetic alopecia and acne. Founded in 2017, the company's lead candidate, ADA-308, is designed as a locally acting, potent antiandrogen to minimize systemic side effects, a key advantage over existing oral therapies. The company targets large dermatology markets with high unmet need, as current treatments for hair loss and acne often involve systemic hormonal modulation or limited efficacy. Aranda's approach leverages tissue-specific androgen receptor inhibition, potentially offering a safer and more effective topical solution. The company is privately held and has not disclosed funding details, but its focus on dermatological indications aligns with growing demand for non-invasive, targeted therapies.

Upcoming Catalysts (preview)

• 2027IND-enabling studies completion and regulatory filing30% success
• TBDPartnership or licensing deal for ADA-30825% success
• 2026Series A or B financing round50% success